Mouse Anti-Mouse PD-1 (29F.1A12) Recombinant Antibody

Product Specifications

Background

Programmed death-1 (PD-1), also know as CD279 is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Like the clones RMP1-14 and J43 antibodies, the 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo.

Product Name Alternative

Programmed cell death protein 1, Pdcd1, CD279

UniProt

Q02242

Host

Mouse

Reactivity

Mouse

Immunogen

PD-1 cDNA followed by PD-1-Ig fusion protein

Target

PD-1

Isotype

IgG2a

Clone

29F.1A12

Applications

Flow Cytometry, Western Blot, Blocking, IHC (Frozen)

Purification Method

This monoclonal antibody was purified using Protein A

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Shipping Conditions

Blue ice

Storage Conditions

Anti-PD-1 In Vivo Antibody - Low Endotoxin (29F.1A12) is stable when stored at 2-8°C for at least four (4) weeks. For long-term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Specificity

Anti-PD-1 In Vivo Antibody - Low Endotoxin (29F.1A12) recognizes an epitope on Mouse PD-1. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.

Formulation

0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added.

Antigen Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.Subset of double negative thymocytes, activated T and B cells

Aggregation

Aggregation level ≤ 5%

Applications Notes

Western Blotting: To detect Mouse PD-1 this antibody can be used at a concentration of 30 μg/ml. Blocking: The 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo. For immune checkpoint antibodies 200 ug per mouse per injection is the standard dosage in the literature. NOTE: The response is model dependent. We have seen some tumor lines in mice that grow progressively. If we treat the animal with anti-PD-1 (days 3,6,9 @ 200 ug per animal per injection) then the tumor will regress, and disappear. Each investigator should determine their own optimal working dilution for specific applications.